Pfizer Works With Roche To Increase Diagnostic Services For Xalkori Launch In China’s Self-Pay Market
This article was originally published in The Pink Sheet Daily
Despite no reimbursement in sight, Pfizer still sees a huge potential for targeted lung cancer drug Xalkori in China. To quickly ramp up eligible patients, Pfizer is working with Roche to offer discounted diagnostic services to identify best responders.
You may also be interested in...
Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.